The stock of XOMA Corp (NASDAQ:XOMA) hit a new 52-week low and has $4.70 target or 13.00% below today’s $5.40 share price. The 5 months bearish chart indicates high risk for the $32.56 million company. The 1-year low was reported on Oct, 19 by Barchart.com. If the $4.70 price target is reached, the company will be worth $4.23M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 79,898 shares traded hands or 33.91% up from the average. XOMA Corp (NASDAQ:XOMA) has declined 60.00% since March 16, 2016 and is downtrending. It has underperformed by 65.54% the S&P500.
Analysts await XOMA Corp (NASDAQ:XOMA) to report earnings on November, 3. They expect $-0.12 earnings per share, up 33.33% or $0.06 from last year’s $-0.18 per share. After $-0.13 actual earnings per share reported by XOMA Corp for the previous quarter, Wall Street now forecasts -7.69% EPS growth.
XOMA Corp (NASDAQ:XOMA) Ratings Coverage
Out of 5 analysts covering Xoma Limited (NASDAQ:XOMA), 1 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 20% are positive. Xoma Limited has been the topic of 8 analyst reports since July 23, 2015 according to StockzIntelligence Inc. Wedbush maintained the shares of XOMA in a report on Wednesday, August 5 with “Buy” rating. On Wednesday, July 22 the stock rating was downgraded by Ladenburg Thalmann to “Neutral”. Jefferies downgraded XOMA Corp (NASDAQ:XOMA) on Thursday, July 23 to “Hold” rating. On Friday, September 4 the stock rating was downgraded by Zacks to “Hold”. Piper Jaffray downgraded the stock to “Neutral” rating in Wednesday, July 22 report. The company was downgraded on Friday, August 28 by Zacks.
According to Zacks Investment Research, “XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. The company’s flagship product is gevokizumab, a humanized antibody to interleukin-1ÃŸ with potential for the treatment of the inflammatory cause of multiple diseases. XOMA Corporation, formally known as XOMA Ltd., is headquartered in Berkeley, California.”
Insitutional Activity: The institutional sentiment decreased to 0.59 in 2016 Q2. Its down 0.72, from 1.31 in 2016Q1. The ratio worsened, as 22 funds sold all XOMA Corp shares owned while 22 reduced positions. 16 funds bought stakes while 10 increased positions. They now own 20.41 million shares or 36.27% less from 32.03 million shares in 2016Q1.
Lmr Prns Limited Liability Partnership accumulated 0.01% or 114,145 shares. Jpmorgan Chase & holds 0% or 3,916 shares in its portfolio. Cowen reported 113,636 shares or 0% of all its holdings. Moreover, Vanguard Group has 0% invested in XOMA Corp (NASDAQ:XOMA) for 5.32M shares. Two Sigma Securities Limited Liability Com last reported 0.04% of its portfolio in the stock. Deutsche National Bank & Trust Ag holds 0% or 182,178 shares in its portfolio. Blackrock Fund Advsrs accumulated 0% or 19,642 shares. Royal Savings Bank Of Canada accumulated 33,852 shares or 0% of the stock. Raymond James And Assocs holds 0% of its portfolio in XOMA Corp (NASDAQ:XOMA) for 13,013 shares. Commonwealth Equity Incorporated reported 11,082 shares or 0% of all its holdings. Da Davidson last reported 0% of its portfolio in the stock. Wfg Advisors Ltd Partnership last reported 353 shares in the company. Barclays Public Ltd Company, a United Kingdom-based fund reported 10,708 shares. Lucas Mngmt has 10,000 shares for 0% of their US portfolio. Macquarie Group Inc Ltd accumulated 800,000 shares or 0% of the stock.
XOMA Company Profile
XOMA Corporation, incorporated on December 31, 2011, is a development-stage biotechnology firm with a portfolio of therapeutic antibodies. The Firm focuses on the discovery and development of monoclonal antibody therapeutics. The Firm has over five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. The Company’s products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab. The Company’s XOMA 358 is meant for long-acting treatment of hyperinsulinemic hypoglycemia. XOMA 129 is meant for rapid onset, short-acting treatment of severe acute hypoglycemia. The Company’s endocrine portfolio also includes a Phase II-ready product candidate, XOMA 213, targeting the prolactin receptor, as well as research-stage programs targeting the parathyroid receptor (PTH1R) and the adrenal corticotropic hormone (ACTH).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.